Abstract:Purpose: The enhanced relative biological effectiveness (RBE) at the end of the proton range might increase the risk of radiation-induced toxicities. This is of special concern for intracranial treatments where several critical organs at risk (OARs) surround the tumor. In the light of this, a retrospective analysis of dose-averaged linear energy transfer (LETd ) and RBE-weighted dose (DRBE ) distributions was conducted for three clinical cases with suspected treatment-related toxicities following intracranial proton therapy. Alternative treatment strategies aiming to reduce toxicity risks are also presented. Methods: The clinical single-field optimized (SFO) plans were recalculated for 81 error scenarios with a Monte Carlo dose engine. The fractionation DRBE was 1.8 Gy (RBE) in 28 or 30 fractions assuming a constant RBE of 1.1. Two LETd - and α/β-dependent variable RBE models were used for evaluation, including a sensitivity analysis of the α/β parameter. Resulting distributions of DRBE and LETd were analyzed together with normal tissue complication probabilities (NTCPs). Subsequently, four multi-field optimized (MFO) plans, with an additional beam and/or objectives penalizing protons stopping in OARs, were created to investigate the potential reduction of LETd , DRBE , and NTCP. Results: The two variable RBE models agreed well and predicted average RBE values around 1.3 in the toxicity volumes, resulting in an increased near-maximum DRBE of 7-11 Gy (RBE) compared to RBE = 1.1 in the nominal scenario. The corresponding NTCP estimates increased from 0.8%, 0.0%, and 3.7% (RBE = 1.1) to 15.5%, 1.8%, and 45.7% (Wedenberg RBE model) for the three patients, respectively. The MFO plans generally allowed for LETd , DRBE , and NTCP reductions in OARs, without compromising the target dose. Compared to the clinical SFO plans, the maximum reduction in the near-maximum LETd was 56%, 63%, and 72% in the OAR exhibiting the toxicity for the three patients, respectively. Conclusions: Although a direct causality between RBE and toxicity cannot be established here, high LETd and DRBE correlated spatially with the observed toxicities, whereas setup and range uncertainties had a minor impact. Individual factors, which might affect the patient-specific radiosensitivity, were however not included in these calculations. The MFO plans using both an additional beam and proton track-end objectives allowed the largest reductions in LETd , DRBE , and NTCP, and might be future tools for similar cases.

Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy

Voxel-level dosimetry for combined Iodine-131 radiopharmaceutical therapy and external beam radiotherapy treatment paradigms of head and neck cancer

On the significance of the different geometrical and dosimetric parameters in microbeam and minibeam radiation therapy a retrospective evaluation

SU-GG-T-347: Methods to Calculate Organ Doses Due to Scattered Radiation From External Beam Radiation Treatment Using Various Patient Phantoms and Monte Carlo Simulations

A Review of Dosimetry Studies on External-Beam Radiation Treatment with Respect to Second Cancer Induction

Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review

Internal Dosimetry: State of the Art and Research Needed

Quantification of Dosimetry Improvement With or Without Patient Surface Guidance

Potential Hazard Due to Induced Radioactivity Secondary to Radiotherapy: the Report of Task Group 136 of the American Association of Physicists in Medicine

Do we need dosimetry for optimization of theranostics in CNS tumors?

Challenges for the Implementation of Primary Standard Dosimetry in Proton Minibeam Radiation Therapy

Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine

EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses

Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer

Detailed dosimetry calculation for in-vitro experiments and its impact on clinical BNCT

Comparative Analysis of Dosimetry: IMRT versus 3DCRT in Left-Sided Breast Cancer Patients with Considering Some Organs in Out - of - Field Borders

Spatial correlation of linear energy transfer and relative biological effectiveness with suspected treatment-related toxicities following proton therapy for intracranial tumors

Monte Carlo-Based Nanoscale Dosimetry Holds Promise for Radiopharmaceutical Therapy Involving Auger Electron Emitters

Internal Dosimetry Assessment of Beta, Beta/Auger, and Alpha Decaying Radionuclidesin Targeted Radionuclide Therapy for Prostate Cancer: A Simulation Study

An external dosimetry audit programme to credential static and rotational IMRT delivery for clinical trials quality assurance

Impact of kV-cone beam computed tomography dose on DNA repair mechanisms: A pilot study